Plain-English translation of NCT07268131 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a combination treatment for liver cancer that's too large or numerous to fit standard transplant criteria, but can still be surgically removed. The treatment combines a procedure called TACE (which delivers chemotherapy directly to tumors through blood vessels) with an immune-boosting medication called QL1706, given before surgery and continued afterward. The goal is to see if this combination approach can improve outcomes for people with this type of advanced liver cancer.
Many people with liver cancer that exceeds standard transplant size limits still have a chance to be cured with surgery, but outcomes could be better. This trial is testing whether adding immune-boosting medication to the standard chemotherapy injection procedure might help destroy cancer more effectively and prevent it from coming back.
You likely qualify if…
You likely don't qualify if…
You would receive the chemotherapy injection procedure (TACE) combined with the immune-boosting medication at the study center. The immune medication would be given intravenously every three weeks before your surgery. After your surgery, you would continue receiving the immune medication for a period of time. Throughout the trial, you would have regular blood tests and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China